We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byTalon Shugar
Modified over 2 years ago
Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients by Betty Y. Chang, Michelle Francesco, Martin F. M. De Rooij, Padmaja Magadala, Susanne M. Steggerda, Min Mei Huang, Annemieke Kuil, Sarah E. M. Herman, Stella Chang, Steven T. Pals, Wyndham Wilson, Adrian Wiestner, Marcel Spaargaren, Joseph J. Buggy, and Laurence Elias Blood Volume 122(14): October 3, 2013 ©2013 by American Society of Hematology
Transient mobilization of lymphocytes in MCL patients treated with ibrutinib. Chang B Y et al. Blood 2013;122: ©2013 by American Society of Hematology
CD19+CD5+ cells have decreased CXCR4, CD38, and Ki67 expression following ibrutinib treatment. Chang B Y et al. Blood 2013;122: ©2013 by American Society of Hematology
Ibrutinib inhibits migration of MCL cells beneath stromal cells (pseudo-emperipoiesis) and the formation of CXCL12-stimulated cortical actin. Chang B Y et al. Blood 2013;122: ©2013 by American Society of Hematology
Ibrutinib suppresses BCR- and coculture-stimulated signaling and cytokine and chemokine production of MCL cells. Chang B Y et al. Blood 2013;122: ©2013 by American Society of Hematology
Ibrutinib inhibits BCR-activated adhesion of MCL cells. Chang B Y et al. Blood 2013;122: ©2013 by American Society of Hematology
Ibrutinib inhibits CXCL12-/CXCL13-activated adhesion and migration of MCL cells. Chang B Y et al. Blood 2013;122: ©2013 by American Society of Hematology
Ibrutinib inhibits BCR- and chemokine-induced adhesion of primary MCL cells. Chang B Y et al. Blood 2013;122: ©2013 by American Society of Hematology
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL by Arian.
Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men by Bas de Laat, Philip G. de Groot, Ronald H.
MOLECULAR ENDOCRINOLOGY AND IMMUNOLOGY LECTURE 7 - Mechanism of action of growth hormone and prolactin Growth hormone: general actions; receptor; signal.
Chapter 62 Chapter 62 Mechanisms of Bone Destruction in Myeloma Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 12 Chapter 12 Parathyroid Hormone and Parathyroid Hormone-Related Protein Copyright © 2013 Elsevier Inc. All rights reserved.
Immunosuppressive therapy for graft-versus-host disease Mohamad Mohty Institut Paoli-Calmettes, Marseille.
Newer cancer therapies Immunotherapy. Immunotherapy Non-specific immunotherapy Non-specific immunotherapy BCG BCG Cytokines Cytokines Specific immunotherapy.
Chemotherapeutic Treatment Options for Triple Negative Breast Cancer Lauren Barney April 17, 2013.
1 The Kidney in Pregnancy Jeffrey J. Kaufhold, MD FACP Update 2010.
Lymphocyte Migration ©Dr. Colin R.A. Hewitt
Use of the oligonucleotide DSP30 with IL2 in the investigation of low grade B cell lymphoid neoplasms Chris Lowe, Newcastle Cytogenetic abnormalities of.
A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.
Management of Multiple Myeloma Irza Wahid Subdivision of Hematology – Medical Oncology Departement of Internal Medicine Medical Faculty, Andalas University.
Defense Against Infectious Disease. Review Disease- a disruption of homeostasis Infectious disease- caused by a pathogen Pathogen- disease producing organism.
Progress Against Leukemia. 1970–1979 Progress Against Leukemia 1970– : FDA approves doxorubicin.
Statins as Protective Agents for Aortic Endothelial Cells Robert Kreisberg West Liberty State College.
Adacolumn Device for Granulocyte and Monocyte Apheresis Otsuka / JIMRO
Herceptin as a Phase 0 Imaging Example. Phase 0 Trials in Oncology Drug Development Steven M. Larson, M.D. Nuclear Medicine Svc, Department of Radiology.
Progress Against Lymphoma. 1970–1979 Progress Against Lymphoma 1970– : FDA approves doxorubicin, a vital part of combination chemotherapy.
An overview of the differences of different JAK inhibitors Alessandro M. Vannucchi University of Florence, Italy.
Disadvantages of Lactic Acid in Human Performance.
Fig. S1 HUVECs HDFNs HUVECs HDFNs Transwell CM Relative total length ** * control 200ng/ml400ng/ml TIMP-1 100ng/ml * ** GFP WT Mutant TIMP-1 TIMP-1 **
VEGF, recettori e sviluppo di inibitori selettivi Roma, 2-3 febbraio 2006 Raffaella Giavazzi Istituto di Ricerche Faramacologiche MarioNegri.
Transplant Immunobiology Douglas Stahura DO Grandview Hospital November 6, 2002.
COLLINS 1.Weintraub NL, et.al. American Heart Association Council on Clinical Cardiology and Council on Cardiopulmonary, Critical Care, Perioperative.
NADPH oxidase: regulator of host defense and inflammation Brahm Segal, MD Roswell Park Cancer Institute.
Chapter 6 Chapter 6 Development of the Skeleton Copyright © 2013 Elsevier Inc. All rights reserved.
Chapter 46 Chapter 46 Estrogen Deficiency, Postmenopausal Osteoporosis, and Age-Related Bone Loss Copyright © 2013 Elsevier Inc. All rights reserved.
MEDITERRANEAN SCHOOL OF ONCOLOGY Advanced Courses and Seminars LLC e MM oggi: un paradigma per nuovi standard nelle neoplasie ematologiche Orvieto (Terni),
IMMUNOMODULATORS Dr. Manjunath. The Immune Response - why and how ? Discriminate: Self / Non self Destroy: Infectious invaders Dysregulated self (cancers)
© 2016 SlidePlayer.com Inc. All rights reserved.